Today's story
Zydus Lifesciences plans Phase III Desidustat trial sickle cell ICMR
Zydus Lifesciences has received regulatory approval to initiate a 203-day Phase III trial of Desidustat for sickle cell disease in collaboration with ICMR, enrolling 164 patients to assess efficacy and safety of the oral tablet. The move follows successful Phase II results and US FDA Orphan Drug Designation, underscoring a public-private effort to address India's substantial SCD burden.
Health · 6 sources · Jul 23, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About desidustat
Desidustat is a drug for the treatment of anemia of chronic kidney disease. This drug with the brand name Oxemia is discovered and developed by Zydus Life Sciences.
Everything about desidustat →